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Abstract: I n t r o d u c t i o n: Extracellular vesicles (EVs), including circulating microvesicles (MVs) or mi-
croparticles (MPs) and exosomes, derived from cells or platelets are present in the peripheral blood and 
are important elements involved in the activation of the coagulation system, transport of macromolecules 
and intercellular communication. In patients with vascular complications (including diabetes), the number 
of EVs is significantly increased during the acute phase of the disease. However, less is known about EVs 
release in the chronic state of diabetes.
O b j e c t i v e s: To analyse the profile of inflammatory cytokines and angiogenic factors in EVs in diabetic 
patients with ocular and vascular complications.
P a t i e n t s  a n d  m e t h o d s: The study included patients with diabetes and varying degrees of ocular com-
plications including retinopathy (n = 48) and the control group (n = 13). EV-enriched and EV-depleted frac-
tions were obtained from platelet-poor plasma by means of the centrifugation method (16 000 g, for 90 min). 
In screening, the profile of cytokines with pro-angiogenic effects was preliminary assessed using the protein 
microarray technology for controlled diabetic patients — CD, uncontrolled diabetic patients — UD and for 
the control group. In all patients, concentrations of cytokines: RANTES (Regulated on Activation, Normal 
T-cell Expressed and secreted) and Ang-2 (angiopoietin-2) were assayed using the ELISA method. Com-
mon blood and biochemical tests were performed.
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R e s u l t s: In patients with diabetes, analysis of supernatant revealed significantly increased concentra-
tions of basic fibroblast growth factor (bFGF) and soluble receptor for vascular endothelial growth factor 2 
(V-EGFR2) when compared to the control group: 49 (10.5–122) vs. 24 (2–72.5) SD (p = 0.03) and 260 
(195.5–351) vs. 360 (256–461.5) SD (p = 0.01). In UD patients, concentrations of RANTES, angiostatin, 
tumor necrosis factor-α (TNF), and tissue inhibitors of metalloproteinase 1 and 2 (TIMP1 and TIMP2) were 
relatively higher in the EV-enriched fraction when compared to the EV-depleted fraction. Post hoc analysis 
revealed significant differences between UC patients and the control group in RANTES (16.73 (14.41–18.93) 
vs. 14.62 (12.37–15.28) mg/ml; p = 0.0235) and Ang-2 (2.76 (2.23–4.64) ng/ml vs. 1.74 (1.54–1.93); 
p = 0.0316) concentrations. These analyses did not reveal any significant differences in RANTES and Ang-2 
concentrations between CD patients and the control group.
C o n c l u s i o n s: The profiles of cytokines and angiogenic factors in EVs are significantly increased in pa-
tients with diabetes. Also, the formation of specific cytokines related to EVs is strongly influenced by disease 
duration and successful treatment. EVs seem to be the conveyors of upregulated cytokines and angiogenic 
agents in diabetic patients.
Key words: Extracellular vesicles (EVs), diabetes, retinopathy, cytokines, RANTES, Angiopoietin-2.
Introduction
Diabetic complications are currently one of the more serious social problems in Poland. 
Mortality and varying degrees of disability, which are a consequence of diabetic compli-
cations, are not only a major health issue but also can generate a number of social and 
economic problems. Currently, it is estimated that approximately 3 million Poles suffer 
from diabetes. Diabetes causes a high risk of vascular complications, of which up to 41% 
include eye damage [1]. Consequently, prevention and early diagnosis may play a very 
important role to achieve an improved therapeutic effect by determining new ways of 
effective treatment. The macula is a very small area at the centre of the retina, responsible 
for pinpoint vision. The main cause of blindness in the diabetic population is maculop-
athy, usually preceded by macular edema. This is the one of very primary symptoms of 
diabetic retinopathy developed when blood vessels in the retina are leaking fluids and 
cause hypoxia without perfusion of the retina [2]. It is suggested that hyperglycemia and 
hypoxia may interact via a common metabolic imbalance to initiate and exacerbate some 
complications and increase free NADH/NAD_c, which appears a candidate entangling 
metabolite causing complications of diabetes [3]. However, the mechanism of how local 
retinal hypoxia is associated with hyperglycemic conditions in diabetes is still poorly un-
derstood [4]. A wide range of phenomena that contribute to diabetic retinopathy includes 
the inflammatory response and increased permeability of the blood-retina barrier [5]. 
They can involve multiple factors that finally produce local changes in microcirculation 
and stimulate angiogenesis — the formation of new blood vessels [4, 5].
Currently, increased attention is focused on the development of new directions 
for retinopathy treatment based on the fundamentals of the anti-inflammatory and 
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anti-angiogenic approach [6]. Current research is also focused on extracellular vesicles 
(EVs), which are thought to have an increasingly important role in the progression of 
diabetic complications [7, 8]. EVs are considered to be not only a biomarker but also 
a therapeutic target in diabetic retinopathy [9].
In our study, we conducted experiments to find a meaningful link between the in-
flammatory state, angiogenesis and circulating EVs. Our working hypothesis assumed 
that in patients with some vascular diabetic complications (retinopathy), circulating 
EVs can participate in the transport of inflammatory cytokines and selected angiogenic 
factors [10]. To test such a formulated hypothesis we planned to perform a screening 
experiment to select specific angiogenic and inflammatory cytokines in the EV-enriched 
fraction of plasma obtained from patients with controlled diabetes mellitus (CD), un-
controlled diabetes mellitus (UD), and from the control group. Then, we quantitatively 
analyzed the expression of the cytokine regulated on activation, normal T-cell expressed 
and secreted (RANTES) and the angiogenic factor, the role of which is also related to 
endothelial dysfunction — angiopoietin-2 (Ang-2) in an extended group of patients 
with vascular complications with respect to control subjects.
Materials and methods
Study group
Twelve patients aged 40 to 64 years were enrolled into the screening study. The partic-
ipants were classified into 3 groups: CD — controlled diabetes type 2 (n = 4); UD — 
uncontrolled diabetes type 2 (n = 4), and the control group which included healthy 
subjects (n = 4). The inclusion criteria were described in our previous paper [11]. The 
study groups were allocated according to the criterion of glycated hemoglobin (HbA1c) 
levels. According to the Polish Diabetes Association guidelines for 2014, an HbA1c lev-
el of 7% is a general criterion of carbohydrate metabolism compensation. Patients in 
whom glycated hemoglobin levels exceed 7% are considered as they have poorly con-
trolled glucose management and they were assigned to the UD group [12]. All patients 
underwent medical examination and a structured interview to investigate any family 
history of vascular and cancer diseases, smoking and use of medications. In the screen-
ing group, 1 patient only had 1 microangiopathy disorder — retinopathy; 4 patients had 
2 disorders: retinopathy and nephropathy; 2 patients had 2 types of vascular complica-
tions: microangiopathy and macroangiopathy, 1 patient had a disorder in the form of 
macroangiopathy only. The characteristics of the study and control groups used for the 
screening is presented in Table 1.
For the quantitative study, an extended group of 61 patients was analyzed including 
diabetic patients (n = 48) and controls (n = 13). Their demographic and clinical charac-
teristics is presented in Table 3. In that group, 11 patients had only 1 microangiopathy 
disorder: retinopathy; 9 patients had 2 disorders: retinopathy and nephropathy; 2 patients 
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had 2 types of disorders: microangiopathy and macroangiopathy disorders, and 16 pa-
tients had a disorder only in the form of macroangiopathy.
Patients were recruited for the study from the Private Ophthalmology Practice 
OKO-LASER Outpatient Clinic (Krakow, Poland) and Department of Intervention-
al Cardiology, American Heart of Poland SA (Chrzanów, Poland). The study was 
approved by the Ethics Committee of the Jagiellonian University Medical College 
(No. KBET/260/B/2013).
Sample collection
All blood samples were drawn at the same time of the day (between 08:00 and 10:00 am) 
by venipuncture of the antecubital vein with a > 21-gauge needle following application 
of a light tourniquet. The first 2–3 ml of blood was not included for EV analysis. The 
Table 1. Characteristics of the screening study group in comparison with the control group.
Diabetes Mellitus  
n = 8
Control 
n = 4 P
Age (years) 61.5 (59.5–65.5)
56 
(53–58.5) 0.104
BMI (kg/m2) 26.87 (25.36–31.59)
24.03 
(21.99–29.93) 0.445
Sex (men/women) 5/3 2/2 0.766
TC (mmol/l) 5.00 (4.07–7.26)
6.53 
(5.88–6.99) 0.552
LDL-C (mmol/l) 2.88 (2.23–4.02)
4.51 
(3.48–5.15) 0.203
HDL-C (mmol/l) 1.21 (1.02–1.45)
1.27 
(1.06–1.67) 0.734
TG (mmol/l) 1.62 (0.93–3.25)
1.77 
(1.22–2.11) 0.932
Glucose (mmol/l) 12.65 (7.65–17.5)
5.70 
(5.00–6.25) 0.034
HbA1C (%) 8.25 (6.6–10.75) NA –
Creatinine (µmol/l) 89.91 (77.1–117.1)
69.5 
(64.5–75) 0.043
hsCRP (mg/l) 1.62 (0.93–2.89)
2.17 
(1.94–2.84) 0.445
Values are given as median (Q1–Q3). Abbreviations: BMI, body mass index; hsCRP, high sensitivity C-reactive protein; 
HbA1C, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
TC, total cholesterol; TG, triglycerides. Bold means statistically significant differences between the groups.
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blood collected into tri-sodium citrate tubes was centrifuged twice at 2500×g for 15 min 
to obtain platelet-poor plasma (PPP). For hematology and HbA1C, EDTA was used as 
an anticoagulant. For biochemistry and biomarkers, the blood was collected in serum 
separator tubes (SST). The plasma and serum samples were aliquoted and frozen at 
–80°C for further analyses.
For the analysis of EVs (including MVs or MPs and exosomes), 300 mL of PPP 
was thawed in water bath at 37oC to avoid cryoprecipitation, mixed and centrifuged at 
16 000×g for 90 minutes at 4°C to obtain the EV-enriched fraction in the lower part of 
the supernatant (first 50 µl above the pellet). The rest of the supernatant was considered 
the EV-depleted fraction. The pellet containing apoptotic bodies and residual platelets 
was removed (Fig. 1).
Fig. 1. Schematic representation of centrifugation protocol and analysis workflow. The figure was produced 
using Servier Medical Art.
Laboratory analyses
Standard blood tests including biochemistry (e.g. triglycerides, LDL-C, HDL-C) were 
performed on the MaxMat analyzer using ELITech Clinical Systems tests (Puteaux, 
France). Detection limit of this method was 0.06 mmol/l. For high-sensitivity C-reactive 
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protein, the APTEC Ultra Sensitive CRP test was used (APTEC Diagnostics nv, Belgium). 
Detection limit of this method was 0.13 mg/l. HbA1C concentration was measured on 
D-10 analyzer (D-10 Hemoglobin Testing System, Bio-Rad Laboratories, Inc, California, 
USA). This method is certified by the NGSP.
As a screening tool to compare expression levels of variety of proteins (cytokines, 
growth factors, proteases, soluble receptors, and other proteins), the Membrane-Based 
Human Angiogenesis Antibody Arrays by RayBiotech, Inc (cat. No AAH-ANG-1000-8, 
C-Series) were used. Chemiluminescence was detected by means of the EC3 BioSpec-
trum Imaging System (UVP, Jena, Germany) equipped with the Vision Works LS software. 
Semi-quantitative analysis was performed using Image J software with the Protein Array 
Analysis plugin by Gilles Carpentier [13]. Data are expressed as signal density [SD] units.
Quantitative analyses of selected factors were performed using commercially avail-
able immunoenzymatic assays (ELISA). RANTES (cytokine Regulated on Activation, 
Normal T-cell Expressed and Secreted) levels were determined by means of Human 
RANTES ELISA Kit (cat No 201-12-0085; SUN RED Biological Technology, Shanghai, 
China). Angiopoietin-2 (Ang-2) levels were determined by means of the Qantikine ELI-
SA Human Angiopoietin-2 kit (cat. No DANG20; R&D Systems, Minneapolis, USA).
Statistical analysis of biochemical and epidemiological parameters
All analyses were carried out with Statistica version 10.0 (StatSoft Inc. USA). Array results 
are presented as median with interquartile range (Q1–Q3). To compare diabetic patients 
with the control, ANOVA analysis and the Kruskal-Wallis test were performed. For all 
results, the Shapiro-Wilk test was performed for testing the sample normal distribution. 
Continuous variables were presented as mean ±SD or median with interquartile range 
(Q1–Q3). Variables were compared by the unpaired t-test or the Mann-Whitney U (con-
tinuous) test or by the Fisher’s exact test or chi-square test (categorical). A Duncan’s post-
hoc multiple range test was performed to analyze the non-interactive effect of diabetes 
duration and biomarker concentrations. P-values below 0.05 were considered significant.
Results
Screening microarray tests included semi-quantitative analyses of cytokines and angio-
genic factors levels, both in the EV-enriched fraction (EVs) and in supernatant. At first, 
differences between patients with diabetes mellitus and the control group were analyzed 
(Table 1). Diabetic patients having vascular complications were characterized by a sig-
nificant increase in Ang-2 (71 (27–127) vs. 33.5 (9.5–63) SD; p = 0.044), basic fibroblast 
growth factor — b-FGF (58 (18.5–134.5) vs. 19 (0–64.5) SD; p = 0.035), thrombopoie-
tin — THPO (55 (27–128) vs.12.5 (2–49.5 SD); p = 0.008), receptor of urokinase-type 
plasminogen activator receptor — u-PAR (208 (133.5–237) vs. 121 (82–150.5 SD); 
Aleksandra Tokarz, Iwona Szuścik, et al.
41
p = 0.034), vascular endothelial growth factor — VEGF (58.5 (14–110) vs. 15.5 (0–57) SD; 
p = 0.036) levels in supernatant and EV fraction (Fig. 2 A and C).
In the EV fraction, diabetic patients had lower vascular endothelial growth factor 
type 3 receptor (VEGFR-3) levels in comparison to control subjects (352.5 (261–417.5) 
vs. 349 (298.5–498) SD; p = 0.004) (Fig. 2 B and D). In plasma depleted of EVs, higher 
b-FGF levels were observed when compared to controls (49 (10.5–122) vs. 24 (2–72.5) S; 
p = 0.03). However, VEGFR2 levels were lower in diabetes patients than in control sub-
jects (260 (195.5–351) vs. 360 (256–461.5) SD; p = 0.01).
Fig. 2. Visual representation of protein microarray images.
The signal intensity for each pair of spots is proportional to the concentration of the antigen in the sample. Expres-
sion pattern of proteins in the EV-enriched fraction (A,B) and supernatant from patient plasma (C,D). Representative 
microarrays for UD patient (A,C) and CD patient (B,D) are presented. Chemiluminescence was detected by CCD camera 
and analyzed using Image J software with Protein Array Analysis plugin by Gilles Carpentier. Position C5/L1, C5/L2 
represents angiostatin, C6/L1, C6/L2 — EGF, C2/L5, C2/L6 — RANTES, C4/L5, C4/L6 — TIMP-1, C5/L5, C5/L6 — 
TIMP-2, which are overexpressed in MPs.
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Secondly, significant differences between the groups determined according to the 
HbA1c criteria were considered. The biochemical characteristics of those groups is pre-
sented in Table 2. In the control group and the group of patients with controlled diabetes 
mellitus (CD), no significant differences were observed in the levels of cytokines and 
angiogenic factors measured in the EV fraction and supernatant. However, in the uncon-
trolled diabetes (UD) group, significantly higher levels of RANTES (1101.5 (426–1760) 
vs. 270 (203.5–321) SD; p = 0.007) (Fig. 3 A), angiostatin (381 (287–561) vs. 243 
(183.5–345.5) SD; p = 0.05) (Fig. 3 B), tumor necrosis factor alpha — TNFα 
(212 (143.5–256.5) vs. 143.5 (96.5–180.5) SD; p = 0.046), growth-related oncogene alpha — 
GROα (126.5 (95.5–240.5) vs. 87.5 (64–104.5) SD; p = 0.031) and metallopeptidase inhib-
itors type 1 — TIMP1 (242.5 (231.5–504) vs. 192.5 (89–200) SD; p = 0.013) and type 2 — 
TIMP2 (279 (221–718.5) vs. 206 (159–228) SD; p = 0.031) (Figs. 3 C and D) were observed.
Table 2. Characteristics of controlled diabetes type 2 (CD) and uncontrolled diabetes type 2 (UD) patients 
in comparison with the control group, in the screening study.
CD 
n = 4
UD 
n = 4
C 
n = 4 P
Age (years) 61.5 (61–65)
60.5 
(49–66.5)
56 
(53–58.5) 0.223
BMI (kg/m2) 26.87 (25.1–29.46)
28.82 
(25.36–32.92)
24.03 
(21.99–29.93) 0.368
Sex (men/women) 2/2 3/1 2/2 0.710
TC (mmol/l) 4.07* (3.78–4.5)
7.26* 
(6.21–7.46)
6.53 
(5.88–6.99) 0.049
LDL-C (mmol/l) 2.28 (1.72–2.88)
4.02 
(2.94–5.07)
4.51 
(3.48–5.15) 0.049
HDL-C (mmol/l) 1.14 (0.85–1.33)
1.33 
(1.10–1.59)
1.27 
(1.06–1.67) 1.00
TG (mmol/l) 1.01 (0.76–2.59)
2.29 
(1.53–5.03)
1.77 
(1.22–2.11) 0.368
Glucose (mmol/l) 10.10 (7.65–12.65)
17.5 
(9.65–21.45)
5.70 
(5.00–6.25) 0.049
HbA1C (%) 6.60* (6.25–6.90)
10.75* 
(9.85–12.25) NA 0.018
Creatinine (µmol/l) 75.49 (71.65–97.1)
107.66 
(89.91–126.58)
69.5 
(64.5–75) 0.018
hsCRP (mg/l) 1.48 (0.93–19.44)
2.04 
(1.02–2.89)
2.17 
(1.94–2.84) 0.368
Values are given as median (Q1–Q3). Abbreviations: BMI, body mass index; hsCRP, high sensitivity C-reactive protein; 
HbA1C, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; 
TC, total cholesterol; TG, triglycerides. Bold means statistically significant differences between the three groups. 
*means statistically significant between the subgroups CD and UD (p <0.05).
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Thirdly, quantitative analysis of two selected pro- and anti-angiogenic factors was 
thoroughly performed by means of the ELISA method: angiopoietin-2 (Ang-2) and 
RANTES. Ang-2 is considered to be a vessel stabilizing factor, while RANTES can act 
as a specific anti-angiogenic cytokine. Those studies were completed with the extend-
ed group of patients (n = 61); the epidemiological and clinical characteristics of these 
groups is presented in Table 3 and 4.
The analyses from the extended study confirmed results obtained from the microarrays 
assay. Increased levels of Ang-2 were observed in patients with diabetes in comparison 
with the control group. Significant differences were also observed between the groups 
determined according to the HbA1C criteria.
Post hoc analysis revealed a difference between the UC group and the control one 
in RANTES levels (p = 0.0235) and Ang-2 concentrations (p = 0.0316). These analyses 
did not reveal any significance in RANTES and Ang-2 in CD patients and controls.
Fig. 3. Semi-quantitative analysis of selected angiogenic factors in the EV-enriched fraction (EV) and 
supernatant (S) in plasma from patients with controlled diabetes type 2 (CD) and uncontrolled diabetes type 2 
(UD) in comparison with the control group.
Levels of angiogenic factor shown as Mean ± SEM of signal density [SD] for: RANTES (A), Angiostatin (B), 
TIMP1(C), TIMP2 (D).
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Table 3. Characteristics of the extended study group in comparison with the control group.
Diabetes Mellitus 
n = 48
Control 
n = 13 p
Age (years) 63.02 ± 9.92 52.58 ± 6.96 0.001
BMI (kg/m2) 31.18 ± 5.21 26.14 ± 5.29 0.007
Sex (men/women) 29/19 5/8 0.164
TC (mmol/l) 4.69 ± 1.29 5.53 ± 1.00 0.033
LDL-C (mmol/l) 2.64 ± 1.14 3.53 ± 1.14 0.014
HDL-C (mmol/l) 1.11 (0.94–1.33)
1.45 
(1.31–1.65) 0.002
TG (mmol/l) 1.67 (1.13–2.42)
0.88 
(0.79–1.75) 0.011
Glucose (mmol/l) 10.15 (7.40–12.00)
5.28 
(4.90–5.70) 0.000005
HbA1C (%) 10.04 (7.35–8.45) NA –
Creatinine (µmol/l) 90.54 (80.54–108.56)
71.0 
(60–80) 0.0003
hsCRP (mg/l) 1.51 (0.81–2.98)
0.85 
(0.71–2.14) 0.139
RANTES (µg/ml) 16.77 (14.75–18.7)
14.62 
(12.37–15.28) 0.076
Ang-2 (ng/ml) 2.72 (1.90–4.50)
1.74 
(1.54–1.93) 0.008
Values are given as average ± SD for parametric test or median (Q1–Q3) for nonparametric test. Abbreviations: BMI, 
body mass index; hsCRP, high sensitivity C-reactive protein; HbA1C, glycated hemoglobin; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; RANTES, 
regulated on activation, normal T-cell expressed and secreted; Ang-2,angiopoietin-2; Bold means statistically significant 
differences between the groups.
Table 4. Characteristics of extended subpopulations of controlled diabetes type 2 (CD) and uncontrolled 
diabetes type 2 (UD) patients in comparison with the control group.
CD 
n = 11
UD 
n = 37
Control 
n = 13 p
Age (years) 60.91 ± 7.09* 63.65 ± 10.62* 52.58 ± 6.96* 0.003
BMI (kg/m2) 31.36 ± 5.62* 31.12 ± 5.15* 26.14 ± 5.29* 0.029
Sex (men/women) 7/4 22/15 5/8 0.357
TC (mmol/l) 4.13 ± 0.48* 4.86 ± 1.41 5.53 ± 1.00* 0.024
LDL-C (mmol/l) 2.22 ± 0.59* 2.77 ± 1.24 3.53 ± 1.14* 0.018
HDL-C (mmol/l) 1.16 (0.96–1.34)
1.09* 
(0.93–1.29)
1.45* 
(1.31–1.65) 0.021
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TG (mmol/l) 1.23 (0.83–1.83)
2.02* 
(1.24–2.48)
0.88* 
(0.79–1.75) 0.011
Glucose (mmol/l) 8.2* (6.50–12.00)
10.4* 
(7.90–12.00)
5.28* 
(4.90–5.70) 0.0000
HbA1C (%) 6.70 (6.30–6.90)
8.00 
(7.60–8.60) NA –
Creatinine (µmol/l) 88.29 (74–100.9)
90.99* 
(81.08–109.91)
71.0* 
(60–80) 0.0007
hsCRP (mg/l) 1.65 (0.95–5.52)
1.46 
(0.81–2.8)
0.85 
(0.71–2.14) 0.319
RANTES (µg/ml) 16.89 (15.18–18.20)
16.73* 
(14.41–18.93)
14.62* 
(12.37–15.28) 0.023
Ang-2 (ng/ml) 2.11 (1.58–3.91)
2.76* 
(2.23–4.64)
1.74* 
(1.54–1.93) 0.036
Values are given as average ± SD for parametric test or median (Q1–Q3) for nonparametric test. Abbreviations: BMI, 
body mass index; hsCRP, high sensitivity C-reactive protein; HbA1C, glycated hemoglobin; HDL-C, high-density lipo-
protein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; RANTES, regu-
lated on activation, normal T-cell expressed and secreted; Ang-2, angiopoietin-2 fraction.
Bold means statistically significant differences between the three groups. 
*means statistically significant between the subgroups in post hoc analysis (p <0.05).
Discussion
Our results obtained in the microarray assay in diabetic patients showed increased levels 
of common angiogenic factors like: VEGF, b-FGF, Ang-2. There are a number of data 
concerning the involvement of VEGF and its receptors and bFGF and the angiopoietin 
family in angiogenesis [5, 6, 14]. Additionally, some evidence of dominant involvement 
of these cytokines in the development of blood vessels are often cited and the role of 
VEGF and its receptors was emphasized [4–6]. However, a special role in this process 
should be assigned to Ang-2, which correlates better than Ang-1 with the extent of an-
giogenesis in patients with complicated diabetes [14].
Wohlfart and co-workers (2014) suggested that among typical angiogenesis factors, 
bFGF plays a pivotal role in diabetic retinopathy; it became overexpressed in the reti-
nal tissue in obese Zucker diabetic rats [15]. In our screening study, we observed that 
bFGF was significantly increased in patients with vascular complications; nonetheless it 
was not confirmed that bFGF is transferred via EVs, mostly MVs. The level of bFGF in 
EVs was lower than in plasma depleted of EVs (supernatant). These data are consistent 
with results published by Chen and co-workers showing that bFGF is not abundant 
in MVs derived from human mesenchymal stem cells (MSCs) when compared to the 
parent cells [16]. However, in the EV-enriched plasma fraction from diabetic patients, 
VEGFR3 levels were decreased when compared to the control group. These data suggest 
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that circulating EVs in diabetic patients have a lower pro-angiogenic potential than it 
was previously hypothesized [9, 10].
Among those highly angiogenic factors, in the microarray assay we observed increased 
levels of u-PAR and thromboplastin. Remarkably, in hypoxic conditions, MVs derived 
from MSCs were augmented with u-PAR when compared to normoxic conditions [16]. 
Despite the fact that u-PAR is not a growth factor, its role in angiogenesis is undoubted. 
It is known that u-PAR enhances uPA function by localizing plasmin formation at the 
cell membrane. Thus, the increased expression of u-PAR in the diabetic retina may be 
involved in the breakdown of cell junctions and permeability barrier function [17]. In 
stable coronary artery disease (CAD) patients, thrombopoietin was inversely associated 
with platelet turnover parameters, and diabetes significantly increased its levels [18]. How-
ever, there are no data suggesting the involvement of MVs in thrombopoietin transport.
In our study, we assumed that diabetes mellitus has an influence on the release 
of angiogenic factors and inflammatory cytokines, and appropriate control of glucose 
levels may change the pattern of their transportation via EVs. We observed that in pa-
tients with higher levels of HbA1c (above 7%), increased abundance of anti-angiogenic 
factors was observed in EVs: angiostatin, RANTES, TIMP1 and TIMP2. The increased 
concentration of these factors in the EV-enriched fraction in plasma obtained from UD 
patients may suggest that EVs may participate in anti-angiogenic factors transfer as well. 
To the best of our knowledge, this is the first study showing the relationship between 
TIMP1/2, RANTES and angiostatin, and EV transport. In dogs with hyperglycemia, 
higher concentrations of angiostatin in myocardial interstitial fluid (MIF) correlated 
with impaired collateral perfusion and blocking of angiostatin with specific antibody 
restored endothelial cell tube formation evoked by MIF [19].
RANTES is a chemokine which is strongly related to retinopathy and angiopathy. 
Higher levels of RANTES were observed in patients with non-proliferative retinopathy 
[20]. It acts through two separate receptors: CCR1 and CCR5 [21, 22]. The antiangiogenic 
character of RANTES is achieved by activation of CCR1. The anti-angiogenic effect is 
observed at the beginning of the process [21]. On the other hand, genetic ablation of 
CCR5 results in the inhibition of neovascularization [22]. Consecutively, TIMP1 and 
TIMP2 have specific ability to inhibit endothelial cell morphogenesis. Thus, we may 
assume that TIMP1/2 can prevent neoangiogenesis in diabetic patients [23]. Moreover, 
TIMP2 inhibits bFGF-induced proliferation of microvascular endothelial cells [24].
In our study, we observed that circulating EVs participate in the transfer of both 
pro-angiogenic factors and anti-angiogenic cytokines. We confirmed that the profile of 
angiogenic factors reveals the relevance of blood glucose management in patients with 
diabetes mellitus. In diabetic patients, levels of pro-angiogenic factors are higher than in 
control ones; nevertheless in patients with uncontrolled diabetes levels of anti-angiogenic 
factors are significantly increased. We may assume that in specific conditions, EVs ac-
complish anti-angiogenic activity, which can produce additional vascular complications 
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in patients with poorly controlled glucose levels. Our observations are consistent with 
Yang and co-workers’ study (2008). They reported that lymphocyte-derived MVs inhibit 
angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced 
pathways [25]. Moreover, endothelial-derived MVs negatively affect angiogenesis in vitro 
by inducing oxidative stress [26].
Interestingly, we observed that both RANTES and Ang-2 are upregulated in UD pa-
tients. In our study, we assumed that the HbA1C cut-off for poorly controlled diabetes 
is 7%. The 7% value is recommended as a target value by most of the recommendations 
and is used to discriminate patients with poorly controlled diabetes [12]. We may ac-
cept that even tiny variations in HbA1c levels may reflect EV cargo and influence their 
embarking with angiogenic and inflammatory factors. Taking into consideration our 
observations, we may assume that the EV profile can be used as a marker in prognosis 
and risk evaluation in patients with vascular complications [14, 27].
Additionally, our study suggests that even in unregulated and highly complicated 
diabetes mellitus, some mechanisms are activated which minimize complications. This 
may be a compelling alternative that we should consider when looking for new ways of 
treating and trying to improve the therapeutic effects in diabetic retinopathy.
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